-
Mashup Score: 94
Autologous stem-cell transplantation (ASCT) is considered the standard of care for management of younger patients (ie, younger than 65–70 years) with newly diagnosed mantle cell lymphoma in much of the world. Once associated with a poor overall survival (only 2 years in many reports), mantle cell lymphoma has been the subject of increasingly intense investigational therapies over the past two decades. The first European Mantle Cell Lymphoma Network trial, published in 2005, showed that ASCT prolonged time to progression in younger patients with mantle cell lymphoma.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 150
Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 148
Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 94
Autologous stem-cell transplantation (ASCT) is considered the standard of care for management of younger patients (ie, younger than 65–70 years) with newly diagnosed mantle cell lymphoma in much of the world. Once associated with a poor overall survival (only 2 years in many reports), mantle cell lymphoma has been the subject of increasingly intense investigational therapies over the past two decades. The first European Mantle Cell Lymphoma Network trial, published in 2005, showed that ASCT prolonged time to progression in younger patients with mantle cell lymphoma.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 148
Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 18
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimm unotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL). A trend was observed in favour of Calquence plus chemoimmunotherapy for the secondary
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 56
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Mosunetuzumab is a CD20xCD3 T-cell–engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator assessment, after an overall median follow-up of 3.5 years in patients with relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphoma (iNHL/aNHL) from the dose-escalation stage of a phase I/II study of mosunetuzumab (ClinicalTrials.gov identifier: NCT02500407). Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions - 16 day(s) ago
Key Points. In relapsed MCL, venetoclax-ibrutinib achieves 7-year PFS of 30%, TTF of 39%, OS of 43% and durable remissions in 10/17 respondersElective trea
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 120Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma - 16 day(s) ago
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targ
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials - 21 day(s) ago
Key Points. Acalabrutinib-based regimens achieve long-term efficacy in patients with higher-risk CLL, across all lines of therapySafety profile of acalabru
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Does TRIANGLE take down transplantation in mantle cell lymphoma? - The Lancet https://t.co/F2SMl7ZY8v